Bristol Myers Squibb

We work every day to transform patients’ lives through science. See our community guidelines:

[Bristol Myers Squibb @bmsnews]

#MEDIA: At the 2026 #ESCCongress, we shared new long-term and real-world data in adults with symptomatic obstructive hypertrophic cardiomyopathy, adding to real-world evidence on long-term outcomes for this patient population: https://t.co/itUPL5CSeE

[Bristol Myers Squibb @bmsnews]

We're investing more than $173 million to expand U.S. radiopharmaceutical manufacturing capacity and help deliver next-generation cancer treatments to patients. Led by @RayzeBio, this investment will support jobs and innovation in Indiana. https://t.co/q41fxnf20x #OneBMS

[Bristol Myers Squibb @bmsnews]

@DrVeera51106 Hi, Veera. Thanks for your comment about job opportunities at BMS. To view our current openings and to learn more about working with us, visit: https://t.co/9f2SbjXF3H.

[Bristol Myers Squibb @bmsnews]

#MEDIA: @US_FDA granted accelerated approval to our new CELMoD treatment for relapsed or refractory #MultipleMyeloma in adults, introducing a new class of treatment. https://t.co/AjYS3vF6ac

[Bristol Myers Squibb @bmsnews]

For more than 25 years, the BMS Foundation, an independent charitable organization, has been strengthening health systems in Africa to address adult cancers as well as pediatric cancers and blood disorders. Read how our grantees are making an impact: https://t.co/nxEOQSolOI

[Bristol Myers Squibb @bmsnews]

#MEDIA: Today, we announced a $2.3 billion investment to build a new manufacturing campus in Houston, Texas. Read more: https://t.co/8OKBDoewsW

[Bristol Myers Squibb @bmsnews]

#MEDIA: The @US_FDA accepted a New Drug Application for our second oral investigational treatment for adult patients with relapsed or refractory multiple myeloma. https://t.co/Q1Sr58VOhY

[Bristol Myers Squibb @bmsnews]

@MIMissJackie Our thoughts and deepest sympathy are with you during this difficult time. We would like to hear more about his experience, if you are open to it. Please call us at 1-800-721-5072.

[Bristol Myers Squibb @bmsnews]

At the opening of our NYNJ World Cup 26 Jersey Fan Hub, our mascot Squibby brought the spirit of #BMSWontLose to New Jersey. See how we're standing shoulder to shoulder with our communities to advance progress during #FIFA2026 and beyond: https://t.co/brukvTImNT

[Bristol Myers Squibb @bmsnews]

As the world gets ready for the 2026 #FIFAWorldCup, our fight to see patients win never ends. See why #BMSWontLose at https://t.co/kvyumYhzrj

[Bristol Myers Squibb @bmsnews]

In the 2026 #FIFAWorldCup, every moment counts for players—just like it does for our patients.

Hear CEO Chris Boerner on why #BMSWontLose as we work to deliver the next breakthrough for those waiting: https://t.co/o7fQHn5JRI

[Bristol Myers Squibb @bmsnews]

#MEDIA: Today, we’re launching Investigating Myeloma, a #MultipleMyeloma awareness campaign in partnership with Mariska Hargitay, which spotlights the importance of ongoing scientific innovation, including a research approach called CELMoD. Read more: https://t.co/Rv40HXUaK6

[Bristol Myers Squibb @bmsnews]

#MEDIA: New data will be presented at #ASCO26 for an EGFRxHER3 bispecific antibody-drug conjugate in triple negative breast cancer and in metastatic esophageal squamous cell carcinoma. Read more: https://t.co/oKChV0VgtD

[Bristol Myers Squibb @bmsnews]

#MEDIA: The FDA has accepted for Priority Review an sNDA for our treatment for adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). If approved, this would be the first cardiac myosin inhibitor to treat adolescents with oHCM: https://t.co/BQBYlfQNNM

[Bristol Myers Squibb @bmsnews]

#MEDIA: The European Commission approved the first immunotherapy-based treatment combination for newly diagnosed classical #HodgkinLymphoma in certain adult and pediatric patients. https://t.co/KufWEf79Zw

[Bristol Myers Squibb @bmsnews]

#MEDIA: Announcing late-breaking results at #ASCO26 from a Phase 3 trial evaluating an investigational therapeutic class called CELMoD for adult patients with relapsed or refractory #MultipleMyeloma. Read more: https://t.co/3dzFekdJHC

[Bristol Myers Squibb @bmsnews]

@SolsticeCristo Thank you for letting us know. Please follow our handle so we can send you a direct message.

[Bristol Myers Squibb @bmsnews]

#MEDIA Chicago, here we come. #ASCO26
50+ abstracts. 10+ cancer types. At @ASCO we're sharing the latest data from our oncology portfolio and pipeline. May 29 – June 2. https://t.co/tVjHs42oaM

[Bristol Myers Squibb @bmsnews]

#MEDIA: Today, we announced European Commission approval of our oral treatment for adults living with active psoriatic arthritis (PsA) who have had an inadequate response or have been intolerant to prior disease-modifying antirheumatic therapy. Read more: https://t.co/Pct9DrihyT

[Bristol Myers Squibb @bmsnews]

Today, we kick off #BMSWontLose, where the energy of the 2026 #FIFAWorldCup meets the urgency of our mission to transform bold science into wins for patients around the globe. Discover more at https://t.co/kvyumYhzrj.